Evidence map›Paper›PMID 37557954›Full record

ArticleJournal of advanced research2024

Modifications of lipid pathways restrict SARS-CoV-2 propagation in human induced pluripotent stem cell-derived 3D airway organoids.

Ping-Hsing Tsai, Jun-Ren Sun, Yueh Chien, Man Sheung Chan, Winnie Khor, Hsin-Chou Yang, Chih-Heng Huang, Chia-Ni Hsiung, Teh-Yang Hwa, Yi-Ying Lin and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Membrane-Targeting Antivirals.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 3 countries.

Ping-Hsing TsaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
Jun-Ren SunInstitute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan; Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei, Taiwan.
Yueh ChienDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Man Sheung ChanDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Winnie KhorDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Hsin-Chou YangInstitute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan.
Chih-Heng HuangInstitute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan; Department of Microbiology and Immunology, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan.
Chia-Ni HsiungInstitute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan.
Teh-Yang HwaInstitute of Statistical Science, Academia Sinica, Taipei 11529, Taiwan.
Yi-Ying LinDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Chih-Ling YehDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Mong-Lien WangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
Yi-Ping YangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
Yuh-Min ChenDepartment of Chest Medicine, Taipei Veterans General Hospital, Taipei 112, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Fu-Ting TsaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Meng-Shiue LeeDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
Yun-Hsiang ChengInstitute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan; Department of Physiology and Biophysics, Graduate Institute of Physiology, National Defense Medical Center, Taipei, Taiwan.
Shan-Ko TsaiInstitute of Preventive Medicine, National Defense Medical Center, Taipei 11217, Taiwan.
Ping-Cheng LiuDepartment of Microbiology and Immunology, National Defense Medical Center, Taipei 11217, Taiwan; Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei, Taiwan.
Shih-Jie ChouDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. Electronic address: sjchou3@vghtpe.gov.tw.
Shih-Hwa ChiouDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; Institute of Pharmacology, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. Electronic address: shchiou@vghtpe.gov.tw.
Taipei Veterans General Hospital · TWNational Yang Ming Chiao Tung University · TWInstitute of Statistical Science, Academia Sinica · TWNational Defense Medical Center · TWCzech Academy of Sciences, Institute of Physiology · CZNational Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundModifications of lipid metabolism were closely associated with the manifestations and prognosis of coronavirus disease of 2019 (COVID-19). Pre-existing metabolic conditions exacerbated the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection while modulations of aberrant lipid metabolisms alleviated the manifestations. To elucidate the underlying mechanisms, an experimental platform that reproduces human respiratory physiology is required.

methodsHere we generated induced pluripotent stem cell-derived airway organoids (iPSC-AOs) that resemble the human native airway. Single-cell sequencing (ScRNAseq) and microscopic examination verified the cellular heterogeneity and microstructures of iPSC-AOs, respectively. We subjected iPSC-AOs to SARS-CoV-2 infection and investigated the treatment effect of lipid modifiers statin drugs on viral pathogenesis, gene expression, and the intracellular trafficking of the SARS-CoV-2 entry receptor angiotensin-converting enzyme-2 (ACE-2).

resultsIn SARS-CoV-2-infected iPSC-AOs, immunofluorescence staining detected the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins and bioinformatics analysis further showed the aberrant enrichment of lipid-associated pathways. In addition, SARS-CoV-2 hijacked the host RNA replication machinery and generated the new isoforms of a high-density lipoprotein constituent apolipoprotein A1 (APOA1) and the virus-scavenging protein deleted in malignant brain tumors 1 (DMBT1). Manipulating lipid homeostasis using cholesterol-lowering drugs (e.g. Statins) relocated the viral entry receptor angiotensin-converting enzyme-2 (ACE-2) and decreased N protein expression, leading to the reduction of SARS-CoV-2 entry and replication. The same lipid modifications suppressed the entry of luciferase-expressing SARS-CoV-2 pseudoviruses containing the S proteins derived from different SARS-CoV-2 variants, i.e. wild-type, alpha, delta, and omicron.

conclusionsTogether, our data demonstrated that modifications of lipid pathways restrict SARS-CoV-2 propagation in the iPSC-AOs, which the inhibition is speculated through the translocation of ACE2 from the cell membrane to the cytosol. Considering the highly frequent mutation and generation of SARS-CoV-2 variants, targeting host metabolisms of cholesterol or other lipids may represent an alternative approach against SARS-CoV-2 infection.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19Induced Pluripotent Stem CellsLipid MetabolismOrganoidsSARS-CoV-2HumansHydroxymethylglutaryl-CoA Reductase InhibitorsVirus ReplicationACE2 protein, humanAngiotensin-Converting Enzyme 2Hydroxymethylglutaryl-CoA Reductase InhibitorsAirway organoidAngiotensin-converting enzyme 2Induced pluripotent stem cellSevere acute respiratory syndrome coronavirus 2Single cell RNA-sequencing

Identifiers

PMID37557954
PMCPMC11156708
OpenAlexW4385660429

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.